Literature DB >> 21069273

[Acoustic neuroma (vestibular schwannoma) therapy from an oto-rhino-laryngological perspective].

K Schwager1.   

Abstract

Acoustic neuroma/vestibular schwannoma treatment has changed considerably since the 1990s, when surgical treatment was recommended in all cases of schwannoma, whereas nowadays a more differentiated approach is taken. The three classical approaches (translabyrinthine, transtemporal, and suboccipital) still have their surgical value; however, greater importance is apportioned to radiotherapy (radiosurgery, gamma- and cyber-knife). Magnetic resonance imaging in particular has changed diagnostics and how tumor growth is followed. Electrophysiological monitoring of facial and auditory nerves has helped lower postoperative morbidity. New issues have been raised regarding quality of life. Neuropsychological investigations for cognitive and mnestic performance following procedures in the cerebellopontine angle have highlighted problem areas receiving hitherto little attention. Finally, the therapy of this benign lesion should be planned individually, taking the patient's age as well as their professional and personal status into consideration.

Entities:  

Mesh:

Year:  2011        PMID: 21069273     DOI: 10.1007/s00106-010-2190-y

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  29 in total

1.  [An index for paresis and defective healing--an easily applied method for objectively determining therapeutic results in facial paresis (author's transl)].

Authors:  E Stennert; C H Limberg; K P Frentrup
Journal:  HNO       Date:  1977-07       Impact factor: 1.284

2.  Headache: a quality of life analysis in a cohort of 1,657 patients undergoing acoustic neuroma surgery, results from the acoustic neuroma association.

Authors:  John Martin Ryzenman; Myles L Pensak; John M Tew
Journal:  Laryngoscope       Date:  2005-04       Impact factor: 3.325

3.  Assessment of dysequilibrium after acoustic neuroma removal.

Authors:  S G Lynn; C L Driscoll; S G Harner; C W Beatty; E J Atkinson
Journal:  Am J Otol       Date:  1999-07

4.  [Functional results, cognitive and effective quality of life disturbances after trans-temporal resection of acoustic neuroma].

Authors:  A Minovi; R Mangold; M Kollert; E Hofmann; W Draf; U Bockmühl
Journal:  Laryngorhinootologie       Date:  2005-12       Impact factor: 1.057

5.  Headaches after acoustic neuroma surgery.

Authors:  T Rimaaja; M Haanpää; G Blomstedt; M Färkkilä
Journal:  Cephalalgia       Date:  2007-08-17       Impact factor: 6.292

6.  [Modification of the retrolabyrinthine approach with hearing preservation in CPA tumors].

Authors:  J Schipper; P Lohnstein; W Stummer; F Knapp; B Turowski; T Klenzner
Journal:  Laryngorhinootologie       Date:  2009-08-28       Impact factor: 1.057

7.  Middle fossa versus retrosigmoid-transmeatal approach in vestibular schwannoma surgery: a prospective study.

Authors:  Vittorio Colletti; Francesco Fiorino
Journal:  Otol Neurotol       Date:  2003-11       Impact factor: 2.311

8.  Effect of tumor removal on tinnitus in patients with vestibular schwannoma.

Authors:  Katsuharu Kameda; Tadahisa Shono; Kimiaki Hashiguchi; Fumiaki Yoshida; Tomio Sasaki
Journal:  J Neurosurg       Date:  2010-01       Impact factor: 5.115

9.  Committee on Hearing and Equilibrium guidelines for the evaluation of hearing preservation in acoustic neuroma (vestibular schwannoma). American Academy of Otolaryngology-Head and Neck Surgery Foundation, INC.

Authors: 
Journal:  Otolaryngol Head Neck Surg       Date:  1995-09       Impact factor: 3.497

10.  Hearing preservation after translabyrinthine approach performed to remove a large vestibular schwannoma.

Authors:  Stéphane Tringali; Chantal Ferber-Viart; Stéphane Gallégo; Christian Dubreuil
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-03-08       Impact factor: 2.503

View more
  1 in total

1.  [Vestibular schwannoma. Part 2: therapy, prognosis, and rehabilitation].

Authors:  W Maier; F Hassepaß; A Aschendorff; R Laszig
Journal:  HNO       Date:  2012-10       Impact factor: 1.284

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.